US Patent 7,803,931: Claim Scope, Patent Strength, Exclusivity and Competitive Landscape

US Patent 7,803,931 protects defined PEGylated aptamer molecules and pharmaceutical compositions containing them. Its strongest protection is claim 1, which requires a specific nucleotide sequence, a 40 kDa PEG polymer, and attachment through a linker at the aptamer's 5' end. Claim 5 narrows that protection to branched 40 kDa PEG. The patent does not, based on the supplied claims, cover all aptamers, all PEG sizes, unmodified sequence variants, manufacturing methods, dosing regimens, or a general therapeutic method of use.

The claims are associated with the ARC1779 development program, a PEGylated aptamer directed against von Willebrand factor. ARC1779 was investigated clinically but was not approved by the FDA. The patent therefore has limited immediate Orange Book or generic-entry relevance, although it remains relevant to development of structurally similar vWF-targeting aptamers and to freedom-to-operate analysis for nucleic-acid therapeutics.

What does US Patent 7,803,931 protect?

The patent contains two principal molecule claims and two composition claims.

Claim	Protected subject matter	Scope
1	Aptamer with nucleotide sequence SEQ ID NO: 4, 40 kDa PEG, and 5' linker attachment	Core molecule claim
2	Compound having a PEGylated aptamer according to SEQ ID NO: 65	Separate PEGylated aptamer claim
3	Therapeutically effective amount of claim 1 or 2, or a salt thereof	Composition claim
4	Claim 3 composition with a pharmaceutically acceptable carrier or diluent	Formulated pharmaceutical composition
5	Claim 1 using branched 40 kDa PEG	Narrower species within claim 1

The supplied claim language should be read with the patent specification, sequence listings, prosecution history, and claim-construction rules. In particular, SEQ ID NO: 4 and SEQ ID NO: 65 must be identified from the patent's sequence listing. The claim numbers alone do not establish the biological target, exact nucleotide length, chemical modifications, linker structure, or all molecular attributes of the claimed aptamers.

How should claim 1 be construed?

Claim 1 requires every element below:

A compound.
The nucleotide sequence of SEQ ID NO: 4.
A PEG polymer having a molecular weight of 40 kDa.
Conjugation through a linker.
Attachment at the 5' end of the nucleotide sequence.

The claim is materially narrower than a claim to any PEGylated aptamer. A competing molecule would have to be assessed against the exact sequence, PEG molecular-weight limitation, linker arrangement, and 5' attachment requirement.

The phrase "consisting of" is significant. It generally signals a closed claim formulation, subject to the meaning given to the term in the specification and prosecution history. It may limit the claimed compound to the recited aptamer-PEG construct and exclude additional structural elements that materially change the compound. It does not necessarily eliminate ordinary impurities, counterions, solvent, or incidental chemical features, but those questions require analysis of the patent record and the accused product.

What does the 40 kDa PEG limitation mean?

The claim requires a PEG polymer of 40 kDa. A substantially different PEG size, such as 20 kDa or 60 kDa, is outside the literal wording of claim 1. A product using a nominally 40 kDa PEG would require analytical review because PEG products are often characterized by average molecular weight and polydispersity rather than a single molecular mass.

The claim does not, on its face, require branched PEG. That limitation appears in dependent claim 5. Claim 1 therefore potentially covers both linear and branched 40 kDa PEG, provided the other limitations are met. Claim 5 captures the branched form as a narrower fallback position.

Does claim 1 cover 3' or internal PEG attachment?

No, not literally. Claim 1 specifies attachment to the nucleotide sequence's 5' end. A 3' conjugate or internally modified aptamer would not satisfy the express 5' attachment limitation, although an equivalent-infringement analysis could depend on the prosecution record and the technical differences between the constructs.

How broad is claim 2 for the SEQ ID NO: 65 aptamer?

Claim 2 covers a compound having the PEGylated aptamer according to SEQ ID NO: 65. Based only on the supplied wording, claim 2 does not expressly repeat the 40 kDa limitation, branched-PEG limitation, or 5' attachment limitation found in claim 1.

That makes claim 2 potentially broader in structural form than claim 1. Its effective scope depends on:

Whether "PEGylated aptamer according to SEQ ID NO: 65" incorporates a defined PEG size from the specification;
Whether the sequence includes chemically modified nucleotides;
Whether the PEG is attached at a defined position;
Whether the claim requires a specific linker;
How the examiner and courts treated the phrase during prosecution.

Claim 2 should not automatically be treated as covering every PEG-conjugated oligonucleotide that resembles SEQ ID NO: 65. The exact sequence and any specification-based definitions remain controlling.

What formulations are protected by claims 3 and 4?

Claim 3 covers a composition containing a therapeutically effective amount of the compound of claim 1 or claim 2, or a salt of that compound. Claim 4 adds a pharmaceutically acceptable carrier or diluent.

These claims protect pharmaceutical compositions, not merely the isolated aptamer. They can be relevant to injectable formulations, liquid solutions, buffered preparations, lyophilized products, and other dosage forms if the composition satisfies the claim limitations.

The claims do not expressly require:

A particular buffer;
A specific pH;
A defined concentration;
A particular injection route;
A specific dosage regimen;
A particular indication;
A stabilizer, surfactant, preservative, or excipient;
A specific container or delivery device.

A formulation containing a claimed aptamer may fall within claim 3 even if it uses a different excipient profile. Claim 4 is narrower because it requires a pharmaceutically acceptable carrier or diluent. A product containing only the active compound without a carrier may still be evaluated under claim 3.

What does claim 5 add to the patent estate?

Claim 5 requires the compound of claim 1 and specifies that the 40 kDa PEG is branched. It is a species claim nested within claim 1.

Feature	Claim 1	Claim 5
SEQ ID NO: 4	Required	Required
PEG	Required	Required
PEG molecular weight	40 kDa	40 kDa
Linker	Required	Required
5' attachment	Required	Required
Branched PEG	Not required	Required

Claim 5 may have practical value where the development product uses branched PEG and the patent owner wants a narrower claim less vulnerable to prior-art attacks directed to linear PEG conjugates. Its commercial value is limited if the broader claim 1 is invalid, expired, or difficult to enforce.

Is US Patent 7,803,931 an Orange Book patent?

No FDA Orange Book listing should be expected for the patent based on the known regulatory history of ARC1779. The Orange Book lists patents submitted for approved small-molecule drug products and certain approved drug-device products. ARC1779 did not obtain FDA approval, and an unapproved aptamer product does not create a conventional Orange Book reference-product framework.[2]

This has several consequences:

There is no approved reference product against which an ANDA applicant could file a standard Paragraph IV challenge.
There is no FDA Orange Book patent-expiration date controlling generic entry.
There is no Hatch-Waxman 30-month stay tied to this patent for an ARC1779 product.
A future developer would face ordinary patent, regulatory, and freedom-to-operate issues rather than a conventional Orange Book certification process.

When does US Patent 7,803,931 lose exclusivity?

The patent issued on September 28, 2010.[1] Its enforceable term is determined by the earliest effective nonprovisional priority date, statutory patent-term adjustment, any terminal disclaimer, and maintenance-fee status. The grant date alone does not establish the expiration date.

The patent is from the pre-AIA period and is expected to have reached, or to be reaching, the end of its ordinary 20-year term in the 2025-2026 period, subject to USPTO term calculations. No FDA pediatric exclusivity or patent-term extension is associated with an approved ARC1779 product.

Exclusivity element	Assessment
Patent term	Near or at ordinary expiration based on the patent family chronology
FDA regulatory exclusivity	None for ARC1779
Orphan-drug exclusivity	No approved ARC1779 product identified
Orange Book listing	Not expected
Biosimilar exclusivity	Not applicable
Pediatric exclusivity	No known applicable period
PTE under 35 U.S.C. §156	No known applicable period

Patent expiration should be confirmed against the USPTO Patent Center continuity and term records before making a launch or enforcement decision.[3]

Are there Paragraph IV challenges or generic litigation?

No conventional Paragraph IV litigation is expected because ARC1779 was not approved and the patent is not being used to block an ANDA for an FDA-approved reference product.

A future competitor could still challenge the patent through:

A declaratory-judgment action;
An infringement action brought by the patent owner;
An inter partes review;
A post-grant validity challenge where legally available;
A noninfringement or invalidity defense in commercial litigation.

The most relevant litigation issues would be claim construction, written description, enablement, anticipation, obviousness, and the precise meaning of the PEG and linker limitations. A competitor using a different sequence, PEG size, attachment site, or conjugation chemistry would have a stronger noninfringement position than a competitor reproducing the claimed construct.

How strong is the patent estate for ARC1779?

The estate is technically narrow but potentially strong against an exact-copy product during its enforceable term.

Risk factor	Assessment
Sequence specificity	Strong against exact sequence replication; weak against meaningfully different sequences
PEG-size limitation	Creates a clear design-around using a different size, but may support infringement where 40 kDa is used
5' attachment	Provides a clear structural boundary
Branched PEG claim	Useful fallback protection for the claimed branched species
Composition claims	Extend risk to drug products containing the claimed molecule
Method-of-use protection	Not present in the supplied claims
Manufacturing protection	Not present in the supplied claims
Regulatory blocking power	Low because there is no approved reference product
Remaining term	Limited or exhausted based on the patent's chronology
Biological platform coverage	Narrow; the claims do not cover all vWF aptamers

The strongest enforcement scenario would involve a product with the same aptamer sequence, 40 kDa PEG, 5' linker attachment, and a therapeutically formulated presentation. The weakest scenario would involve a different aptamer sequence or a different PEG size and conjugation position.

What manufacturing and intellectual-property barriers remain?

Although the claims are molecule-focused, commercial development may face barriers outside this patent:

Reproducible synthesis of long, modified oligonucleotides;
Control of PEGylation-site distribution;
Separation of unconjugated aptamer and unreacted PEG;
Characterization of PEG molecular-weight distribution;
Control of stereochemical and positional isomers;
Stability during storage and administration;
Immunogenicity and pharmacokinetic validation;
Process patents owned by third parties;
Know-how relating to linker chemistry and purification;
Additional patents covering the therapeutic target, formulation, assay, or manufacturing process.

A design-around that avoids claim 1 may still infringe a separate patent family covering the same target, an overlapping sequence motif, a linker, a manufacturing process, or a formulation.

How does this patent compare with pegaptanib and other aptamer estates?

Pegaptanib, marketed as Macugen, is the closest commercial aptamer comparator because it established the regulatory pathway for a PEGylated oligonucleotide drug. Pegaptanib targeted VEGF165 and used a different aptamer sequence and therapeutic indication. Its patent estate included composition, sequence, formulation, and use-related protection developed around an approved product.[4]

Attribute	US 7,803,931 / ARC1779	Pegaptanib / Macugen
Modality	PEGylated aptamer	PEGylated aptamer
Primary target	Associated with vWF-targeting ARC1779 program	VEGF165
FDA approval	None for ARC1779	Approved in 2004
Orange Book relevance	No conventional listing expected	Approved-product patent framework
Core protection	Defined sequences and PEG conjugates	Product and use estate around pegaptanib
Generic pathway	No standard ANDA pathway	Hatch-Waxman pathway potentially available
Commercial status	Development program, not marketed as an approved drug	Commercially established product, later limited by market competition

The comparison shows why a technically valuable aptamer patent can have limited commercial exclusivity if the underlying product never reaches approval.

Which companies challenged or licensed the ARC1779 program?

ARC1779 was developed by Archemix and was subject to commercial development and collaboration arrangements reported publicly during its clinical development. Nuvelo was associated with the program through a collaboration or license arrangement, and later development activity did not produce an approved product.[5]

The public record does not establish an active generic challenger comparable to an ANDA Paragraph IV filer. The principal commercial risk therefore comes from competing drug programs, alternative anticoagulants, and next-generation nucleic-acid therapeutics rather than from a filed generic application.

What generic and biosimilar entry risks exist?

There is no conventional biosimilar pathway because ARC1779 is not an approved biologic reference product. Aptamers are synthetic oligonucleotide medicines and are not ordinarily treated as biosimilars under the Public Health Service Act pathway.

Potential entrants would instead pursue an abbreviated or full FDA route depending on the product, regulatory classification, and availability of a reference product. The principal entry strategies would be:

A structurally distinct aptamer targeting the same biological pathway.
A different PEG size or branching architecture.
A different conjugation site.
A sequence variant with retained binding activity.
A full application supported by independent pharmacology and clinical data.

Patent risk is highest for a literal copy of SEQ ID NO: 4 or SEQ ID NO: 65 using the claimed PEG architecture. It is lower for a distinct sequence and materially different conjugation design.

What is the overall commercial value of US 7,803,931?

The patent has greater historical and technical value than current blocking value. Its claims were directed to a defined PEGylated aptamer product class rather than to a broad therapeutic method or platform.

The practical valuation is affected by four facts:

ARC1779 did not receive FDA approval.
The patent does not provide a conventional Orange Book barrier.
The ordinary patent term is at or near expiration.
No supplied claim covers a manufacturing process, dosage regimen, or broad target-based use.

For diligence purposes, the patent should be classified as a narrow composition patent with residual relevance to exact-structure copying, rather than as a broad, live platform patent capable of blocking all vWF-targeting aptamers.

Key Takeaways

Claim 1 is the principal claim and requires SEQ ID NO: 4, 40 kDa PEG, a linker, and 5' attachment.
Claim 2 separately protects a PEGylated aptamer based on SEQ ID NO: 65, subject to specification-based interpretation.
Claim 5 narrows claim 1 to branched 40 kDa PEG.
Claims 3 and 4 extend protection to therapeutic compositions and formulations.
The supplied claims contain no express manufacturing, dosing, or method-of-use protection.
ARC1779 was not FDA-approved, so the patent has no conventional Orange Book or Paragraph IV role.
The patent's ordinary term is at or near expiration, subject to USPTO patent-term and maintenance records.
Exact-sequence copying presents the highest infringement risk.
Different sequences, PEG sizes, and attachment sites are the clearest design-around pathways.
The patent estate has limited current commercial blocking power compared with an approved-product patent estate such as pegaptanib's.

FAQs

Can a company use the same aptamer with 20 kDa PEG instead of 40 kDa PEG?

A 20 kDa PEG construct would not literally satisfy the 40 kDa limitation in claim 1. Separate patents covering the sequence, linker, formulation, or manufacturing process could still create risk.

Does claim 5 protect every branched PEG aptamer?

No. Claim 5 is limited to the compound of claim 1. It requires SEQ ID NO: 4, a 40 kDa PEG, linker-mediated 5' attachment, and branched PEG architecture.

Does this patent protect treatment of von Willebrand disease?

The supplied claims do not contain a method-of-treatment limitation. They protect compounds and compositions. Separate claims in related patents could address therapeutic use.

Is a salt of the PEGylated aptamer covered?

Claim 3 expressly includes a salt of the compound of claim 1 or claim 2 when present in the claimed therapeutic composition.

Can an FDA-approved competitor be blocked by this patent?

Only if the competitor's product satisfies the asserted claim limitations and the patent remains enforceable. Because the underlying ARC1779 program was not approved and the patent term is near or at expiration, its current regulatory blocking power is limited.

References

United States Patent No. 7,803,931, "Pegylated aptamers." U.S. Patent and Trademark Office. (2010).
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Patent and Trademark Office. (2024). Patent Center and patent term adjustment records.
U.S. Food and Drug Administration. (2004). FDA approves Macugen for treatment of neovascular age-related macular degeneration.
Nuvelo, Inc. (2006-2011). Securities and Exchange Commission filings concerning the ARC1779 development program and collaboration arrangements.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006214437	⤷ Start Trial
Brazil	PI0607002	⤷ Start Trial
Canada	2597889	⤷ Start Trial
Canada	2897900	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,803,931

Summary for Patent: 7,803,931